Publication date: Sep 18, 2023
We evaluated the pharmacokinetics of tenofovir alafenamide fumarate (TAF) and tenofovir in a subset of African children enrolled in the CHAPAS-4 trial. Children aged 3-15 years with human immunodeficiency virus infection failing first-line antiretroviral therapy were randomized to emtricitabine/TAF versus standard-of-care nucleoside reverse transcriptase inhibitor combination, plus dolutegravir, atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. Daily emtricitabine/TAF was dosed according to World Health Organization (WHO)-recommended weight bands: 120/15 mg in children weighing 14 to
| Concepts | Keywords |
|---|---|
| African | children |
| Daily | drug interaction |
| Dolutegravir | HIV |
| Failing | pharmacokinetics |
| Immunodeficiency | TAF |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Tenofovir |
| drug | DRUGBANK | Dolutegravir |
| drug | DRUGBANK | Emtricitabine |
| drug | DRUGBANK | Atazanavir |
| drug | DRUGBANK | Ritonavir |
| drug | DRUGBANK | Darunavir |
| drug | DRUGBANK | Lopinavir |
| disease | VO | organization |
| disease | MESH | drug interaction |
Original Article
(Visited 1 times, 1 visits today)